Ann: PTX Presentation, page-11

Not to mention how many shares directors, chairs and Top SH like Hopper pay for their shares via participation in CRs. The last batch that our CEO bought was at 17.5c. Its equally important, if not more, that the people in charge of running the co. support the financing of operations and pipeline so that the co. can continue its important and valuable work. How much credence does the market really give to token on-market purchases other than on the day of the notice or when the players on social media choose to promote it as a big thing or a bad thing (if the lack thereof exists)?

I think the safety profile of PTX-100 should be the clincher for Ph2 approval and maybe even approval for a registration Ph2/3 trial. Here's the safety issues and efficacy results of Lymphir (the current SOC for CTCL) according to ChatGPT:-